Suchergebnisse - "9G6U5L461Q"

PubPharm (194)

1

Complete pathologic response to neoadjuvant icotinib in stage IIIA EGFR-mutant lung adenosquamous carcinoma : A case report

enthalten in: Medicine | 2024

von Cai, Z. | Huang, J. | Dai, W. | +3

2

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer : a multicentre, open-label, randomised phase 3 study

enthalten in: The Lancet. Respiratory medicine | 2023

von Lu, S. | Zhou, J. | Jian, H. | +41

CommentIn: Lancet Respir Med. 2023 Oct;11(10):857-859. - PMID 37244264

3

A meta-analysis for the efficacy and safety of icotinib combined with radiotherapy in treating brain metastases of non-small cell lung cancer

enthalten in: Medicine | 2023

von Zhang, B.

4

Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study)

enthalten in: ESMO open | 2023

von Lv, C. | Wang, R. | Li, S. | +23

5

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations : final analysis of the prospective phase 2, multicenter ALTER-L004 study

enthalten in: Molecular cancer | 2023

von Zhang, L. | Wang, L. | Wang, J. | +15

6

Rapid vision improvement by using icotinib in a patient with bilateral choroidal metastases symmetrically from lung cancer

enthalten in: The clinical respiratory journal | 2023

von Li, C. | Wang, X. | Yan, L. | +2

7

Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non-small cell lung cancer patients

enthalten in: Investigational new drugs | 2023

von Tan, X. | Wang, S. | Xia, H. | +7

8

Simultaneous online SPE-HPLC-MS/MS quantification of gefitinib, osimertinib and icotinib in dried plasma spots : Application to therapeutic drug monitoring in patients with non-small cell lung cancer

enthalten in: Journal of pharmaceutical and biomedical analysis | 2023

von Jia, M. | Wu, Z. | Shi, W. | +10

9

Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma : a multicenter, open-label, single-arm, phase II study (ICAPE)

enthalten in: Investigational new drugs | 2023

von Qian, K. | Chen, Q. | He, M. | +7

10

Expert consensus on icotinib as adjuvant therapy for non-small cell lung cancer

enthalten in: Zhonghua zhong liu za zhi [Chinese journal of oncology | 2023

von China International Exchange and Promotive Association for Medical and Health Care | Guangdong Association of Thoracic Diseases

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[20]